The impact of electronic cigarettes on the paediatric population

Tobacco Control
|April 16, 2014
PubMed

Insights

Electronic cigarette (e-cigarette) use is rising among children, with limited data on health impacts. E-cigarettes pose risks like nicotine exposure and choking hazards for youth.

Area of Science:

  • Pediatric Health
  • Adolescent Health
  • Tobacco Control

Background:

  • Electronic cigarettes (e-cigarettes) are increasingly popular among youth.
  • Reasons for youth initiation and continued use of e-cigarettes are not well understood.
  • The influence of marketing and flavored liquids on youth e-cigarette use remains unknown.

Purpose of the Study:

  • To review the impact of electronic cigarettes (e-cigarettes) on children.
  • To synthesize current knowledge on youth e-cigarette use and associated risks.

Main Methods:

  • Searched five electronic databases up to December 2013 for studies on children (<18 years).
  • Included relevant data from literature searches, state surveys, and US Food and Drug Administration (FDA) adverse event reports.
  • Reviewed available data on e-cigarette use, initiation, exposure, and adverse events in children.

Main Results:

  • Youth e-cigarette use is increasing and extends beyond traditional smokers.
  • Limited data exist on initiation reasons, marketing effects, and abuse liability in youth.
  • Reports of unintentional exposures and poison center calls related to e-cigarettes are rising; data on secondhand/thirdhand aerosol exposure are absent.

Conclusions:

  • Data on e-cigarette impact on children are scarce, but youth awareness and use are rapidly increasing.
  • Potential risks include nicotine dependence, transition to other tobacco products, unintentional nicotine exposure, and choking hazards.
  • Further research is crucial to understand e-cigarette effects on child health and public health outcomes.
Abstract

Related Concept Videos

Stimulants01:29

Stimulants

Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
1.4K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K